Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
Mallinckrodt
McKinsey
McKesson

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR GLIADEL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Gliadel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003463 ↗ Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas Completed National Cancer Institute (NCI) Phase 1 1998-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.
NCT00003463 ↗ Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas Completed Duke University Phase 1 1998-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine wafers plus irinotecan in treating patients with recurrent supratentorial high grade gliomas.
NCT00003467 ↗ Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed National Cancer Institute (NCI) Phase 2 1998-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.
NCT00003467 ↗ Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma Completed Duke University Phase 2 1998-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gliadel

Condition Name

Condition Name for Gliadel
Intervention Trials
Brain and Central Nervous System Tumors 8
Glioblastoma Multiforme 8
Glioblastoma 5
Refractory Diffuse Large B-Cell Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gliadel
Intervention Trials
Glioblastoma 17
Glioma 16
Lymphoma 13
Lymphoma, Non-Hodgkin 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gliadel

Trials by Country

Trials by Country for Gliadel
Location Trials
United States 170
Canada 10
United Kingdom 4
Germany 3
Israel 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gliadel
Location Trials
North Carolina 15
Washington 12
Texas 11
Ohio 9
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gliadel

Clinical Trial Phase

Clinical Trial Phase for Gliadel
Clinical Trial Phase Trials
Phase 3 6
Phase 2 21
Phase 1/Phase 2 9
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gliadel
Clinical Trial Phase Trials
Completed 23
Terminated 7
Unknown status 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gliadel

Sponsor Name

Sponsor Name for Gliadel
Sponsor Trials
National Cancer Institute (NCI) 25
Fred Hutchinson Cancer Research Center 8
Eisai Inc. 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gliadel
Sponsor Trials
Other 36
NIH 26
Industry 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Medtronic
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.